Company Filing History:
Years Active: 2016
Title: David Azria - Innovator in Cancer Treatment
Introduction
David Azria is a notable inventor based in Mauguio, France. He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. His work focuses on the combined use of specific antibodies to enhance therapeutic efficacy in cancer patients.
Latest Patents
David Azria holds a patent for a groundbreaking invention titled "Combination therapy using anti-EGFR and anti-HER2 antibodies." This invention relates to the combined use of anti-EGFR antibodies and anti-HER2 antibodies for the treatment of cancer. It is particularly suitable for cancers that express high levels of the EGFR type and low levels of HER2. The invention highlights the monoclonal antibody 'trastuzumab' (HERCEPTIN®), which targets HER2 receptors. The efficacy of trastuzumab can be significantly increased in vivo when combined with the monoclonal antibody 'matuzumab' (hmAB 425, EMD 72000), which targets EGF receptors. This combination treatment is especially beneficial for patients suffering from pancreatic cancer who have the specified receptor profile. David Azria has 1 patent to his name.
Career Highlights
Throughout his career, David Azria has worked with prestigious institutions, including the National Institute of Health and Medical Research (Institut National De La Santé Et De La Recherche Médicale). His research has contributed to advancements in cancer therapies, particularly in the area of targeted treatments.
Collaborations
David Azria has collaborated with notable professionals in his field, including Stephen D. Gillies and Christel Larbouret. These collaborations have further enriched his research and development efforts in cancer treatment.
Conclusion
David Azria's innovative work in the field of cancer treatment exemplifies the impact of targeted therapies on patient outcomes. His patented combination therapy represents a significant advancement in the fight against cancer, particularly for those with specific receptor profiles.